J&J vaccine adds to Covid-19 armoury, includes South African variant
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Friday
August 12, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
FRIDAY, AUGUST 12, 2022
J&J vaccine adds to Covid-19 armoury, includes South African variant

Coronavirus chronicle

Reuters
30 January, 2021, 09:15 am
Last modified: 30 January, 2021, 09:20 am

Related News

  • Children aged 5-11 to get Covid jabs from 11 August
  • US FDA authorizes Novavax Covid vaccine for adults
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit

J&J vaccine adds to Covid-19 armoury, includes South African variant

J&J’s main goal was the prevention of moderate to severe Covid-19, and the vaccine was 85% effective in stopping severe disease and preventing hospitalization across all geographies and against multiple variants 28 days after immunization

Reuters
30 January, 2021, 09:15 am
Last modified: 30 January, 2021, 09:20 am
Photo/Collected
Photo/Collected

Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing Covid-19 in a large global trial against multiple variants, giving health officials another weapon to tackle the pandemic.

In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe Covid-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.

The data showed that the vaccine's effect on the South Africa variant was diminished compared to the unaltered virus, but infectious disease and public health experts said it can still help contain the virus spread and prevent deaths.

Midstage trial data from Novavax on Thursday also documented lower effectiveness in South Africa.

Rival shots from Pfizer/BioNTech and Moderna were both around 95% effective in preventing symptomatic illness in pivotal trials when given in two doses.

Those trials were conducted mainly in the United States and before the emergence of new variants. These mean that the world is racing against time and with limited supplies to vaccinate as many people as possible, and quickly, to prevent virus surges.

Covid-19 is rising in 37 countries and infections have surpassed 101 million globally.

Top US infectious disease specialist Anthony Fauci said the world needs to vaccinate quickly to try to get ahead of these changes in the virus.

"It's really a wake up call for us to be nimble and to be able to adjust as this virus will continue for certain to evolve," Fauci said.

J&J's main goal was the prevention of moderate to severe Covid-19, and the vaccine was 85% effective in stopping severe disease and preventing hospitalization across all geographies and against multiple variants 28 days after immunization.

That "will potentially protect hundreds of millions of people from serious and fatal outcomes of Covid-19," Paul Stoffels, J&J's chief scientific officer, said.

J&J shares were down 4% at $162.7 at 1700 GMT, with some Wall Street analysts saying its vaccine's effectiveness was below those of rivals. Moderna's stock gained 8% to $172.80.

Seeking Approval

J&J plans to seek emergency use authorization from the US Food and Drug Administration next week and will soon follow up with the European Union and the rest of the world.

It has said it plans to deliver 1 billion doses of the vaccine, which it will make in the United States, Europe, South Africa and India, in 2021.

Public health officials are counting on it to increase much-needed supply and simplify immunization in the United States, which has a deal to buy 100 million doses of J&J's vaccine and an option for an additional 200 million.

J&J said the vaccine would be ready immediately upon emergency approval, but Stoffels declined to say how many doses.

"The key is not only overall efficacy but specifically efficacy against severe disease, hospitalization, and death," said Walid Gellad, a health policy associate professor at the University of Pittsburgh.

J&J's vaccine uses a common cold virus to introduce coronavirus proteins into cells and trigger an immune response, whereas the Pfizer/BioNTech and Moderna vaccines employ a new technology called messenger RNA.

Unlike these vaccines, J&J's does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world where transportation and cold storage present problems.

"Most countries are still desperate to get their hands on doses, regardless of whether or not the vaccine is considered highly effective. Moderately effective will do just fine for now," Michael Breen, Director of Infectious Diseases and Ophthalmology at research firm GlobalData, said.

'Overwhelmed'

Several studies have emerged this month showing that a South African variant has mutated in areas of the virus that are key targets of vaccines, reducing their efficacy.

"What we are learning is there is different efficacy in different parts of the world," Stoffels told Reuters.

In a sub-study of 6,000 volunteers in South Africa, Stoffels said, the J&J vaccine was 89% effective at preventing severe disease. In the South Africa portion of the trial, 95% of cases were infections with the South African variant.

"I am overwhelmed by the fact that this vaccine protected against severe disease even in South Africa," said Glenda Gray, the joint lead investigator of the South African vaccine trial.

In the J&J trial, which was conducted in eight countries, 44% of participants were from the United States, 41% from Central and South America and 15% from South Africa. Just over a third of the volunteers were over 60.

Top News

J&J Covid-19 Vaccine / J&J / Coronavirus Vaccine / covid-19 vaccine / vaccine data / Vaccine efficacy / Vaccine acceptance / Novavax / Novavax Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Default loans jump Tk22,000cr in six months
    Default loans jump Tk22,000cr in six months
  • File Photo: Mohammad Minhaj Uddin/TBS
    ICDs hike imports handling charge by 35%
  • A shopping cart is seen in a supermarket as inflation affected consumer prices in Manhattan, New York City, US on 10 June 2022. REUTERS/Andrew Kelly
    Is global inflation nearing a peak?

MOST VIEWED

  • In this file photo taken on March 2, 2019, Kim Yo Jong, sister of North Korea's leader Kim Jong Un, attends a wreath-laying ceremony at Ho Chi Minh Mausoleum in Hanoi. Photo: Hindustan Times
    Kim Jong Un's sister warns Seoul of 'retaliation' over Covid
  • North Korean leader Kim Jong Un speaks at a politburo meeting of the Worker's Party on the country's coronavirus disease (COVID-19) outbreak response in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 21, 2022. KCNA via REUTERS
    North Korea declares victory over Covid, suggests leader Kim had it
  • Workers wearing protective suits arrive to a building under lockdown for compulsory testing, following the coronavirus disease (COVID-19) outbreak in Hong Kong, China January 7, 2022. Photo :Reuters
    Hong Kong cuts Covid quarantine stay for incoming travellers
  • People line up for nucleic acid tests during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    China's Sanya holiday hotspot shuts duty-free malls, venues to curb Covid
  • FILE PHOTO: People wearing protective face masks walk amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea May 15, 2020, in this photo released by Kyodo. Mandatory credit Kyodo/via REUTERS
    North Korea marks end of first Covid wave, but risks persist
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    South Africa reports first death causally linked to Covid vaccine

Related News

  • Children aged 5-11 to get Covid jabs from 11 August
  • US FDA authorizes Novavax Covid vaccine for adults
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit

Features

Bye bye! Photographer: Michael Zarrilli/Getty Images North America via Bloomberg

Three major takeaways from the FBI search on Trump’s home

14h | Panorama
Photo: Noor A Alam/TBS

Big dreams in small rooms: The aspiring nurses of Geneva Camp

17h | Panorama
Illustration: TBS

How to deal with toxic people at work

18h | Pursuit
Women were more likely to report leaving the workforce between March 2020 and September 2021 than their male counterparts. PHOTO: BLOOMBERG

Being single and smart is bad for your career if you are a woman

17h | Pursuit

More Videos from TBS

Control on liquor import boosts local Carew sales

Control on liquor import boosts local Carew sales

7h | Videos
Is Bangladesh losing opportunity to sent more expats to the Middle East?

Is Bangladesh losing opportunity to sent more expats to the Middle East?

8h | Videos
When hassles at airport will come to an end?

When hassles at airport will come to an end?

10h | Videos
How to spot a Pyramid Scheme?

How to spot a Pyramid Scheme?

11h | Videos

Most Read

1
Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 
Banking

Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 

2
Diesel price hiked by Tk34 per litre, Octane by Tk46
Energy

Diesel price hiked by Tk34 per litre, Octane by Tk46

3
Photo: Collected
Transport

Will Tokyo’s traffic model solve Dhaka’s gridlocks?

4
Arrest warrant against Habib Group chairman, 4 others 
Crime

Arrest warrant against Habib Group chairman, 4 others 

5
File Photo: State Minister for Power, Energy and Mineral Resources Nasrul Hamid
Energy

All factories to remain closed once a week under rationing system

6
Anwar Group looks beyond slowdown – invests Tk5,000cr
Economy

Anwar Group looks beyond slowdown – invests Tk5,000cr

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]